Denali Therapeutics (NASDAQ:DNLI) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Denali Therapeutics (NASDAQ:DNLI) from a sell rating to a hold rating in a research note issued to investors on Saturday,Wall Street Zen reports.

A number of other equities analysts also recently issued reports on the company. JPMorgan Chase & Co. assumed coverage on Denali Therapeutics in a research note on Monday, July 13th. They set an “overweight” rating and a $29.00 price target for the company. Wedbush reissued an “outperform” rating and issued a $26.00 price objective on shares of Denali Therapeutics in a research note on Monday, July 13th. Morgan Stanley increased their price objective on Denali Therapeutics from $35.00 to $36.00 and gave the stock an “overweight” rating in a research note on Thursday, July 23rd. Deutsche Bank Aktiengesellschaft raised their target price on Denali Therapeutics from $31.00 to $35.00 and gave the company a “buy” rating in a report on Thursday, July 16th. Finally, Robert W. Baird set a $34.00 target price on Denali Therapeutics in a research report on Friday, August 7th. Thirteen research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $35.85.

Denali Therapeutics Price Performance

Shares of DNLI opened at $18.66 on Friday. The business’s fifty day moving average is $21.09 and its 200 day moving average is $21.19. Denali Therapeutics has a 12-month low of $13.75 and a 12-month high of $27.30. The company has a quick ratio of 8.32, a current ratio of 8.37 and a debt-to-equity ratio of 0.01. The stock has a market cap of $2.98 billion, a P/E ratio of -6.57 and a beta of 1.02.

Denali Therapeutics (NASDAQ:DNLI) last issued its quarterly earnings data on Thursday, August 6th. The company reported ($0.68) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.17). The firm had revenue of $3.60 million for the quarter, compared to analysts’ expectations of $2.15 million. During the same period in the prior year, the company earned ($0.72) EPS. Sell-side analysts anticipate that Denali Therapeutics will post -2.70 earnings per share for the current fiscal year.

Insider Buying and Selling

In other news, insider Alexander O. Schuth sold 2,857 shares of the stock in a transaction on Tuesday, August 11th. The stock was sold at an average price of $25.07, for a total transaction of $71,624.99. Following the completion of the transaction, the insider owned 281,763 shares in the company, valued at approximately $7,063,798.41. This represents a 1.00% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders own 9.70% of the company’s stock.

Hedge Funds Weigh In On Denali Therapeutics

A number of large investors have recently made changes to their positions in DNLI. Mitsubishi UFJ Asset Management Co. Ltd. bought a new stake in shares of Denali Therapeutics during the second quarter valued at about $26,000. Global Retirement Partners LLC bought a new position in shares of Denali Therapeutics in the second quarter valued at approximately $28,000. Nykredit A S purchased a new position in Denali Therapeutics during the second quarter valued at approximately $38,000. Allworth Financial LP purchased a new position in Denali Therapeutics during the second quarter valued at approximately $47,000. Finally, Manchester Capital Management LLC increased its holdings in Denali Therapeutics by 5,505.6% during the 3rd quarter. Manchester Capital Management LLC now owns 2,018 shares of the company’s stock worth $42,000 after acquiring an additional 1,982 shares during the period. 92.92% of the stock is owned by institutional investors.

About Denali Therapeutics

Denali Therapeutics Inc is a biopharmaceutical company focused on discovering and developing therapies for patients with neurodegenerative diseases. The company’s research programs target conditions including Parkinson’s disease, Alzheimer’s disease, amyotrophic lateral sclerosis, and lysosomal storage disorders.

Denali uses its blood-brain barrier transport technology, known as the Transport Vehicle platform, to design medicines intended to deliver therapeutic proteins and other biologic treatments into the central nervous system.